» Articles » PMID: 26149923

Clinical and Serological Features of Patients with Dermatomyositis Complicated by Spontaneous Pneumomediastinum

Overview
Journal Clin Rheumatol
Publisher Springer
Specialty Rheumatology
Date 2015 Jul 8
PMID 26149923
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

The purpose of this study was to explore the clinical and serological features of patients with pneumomediastinum (PNM) and dermatomyositis-associated interstitial lung disease (DM-ILD). A total of 93 patients (68 with classic DM and 25 with clinically amyopathic DM [CADM]) were recruited. Clinical and laboratory data were collected retrospectively. Anti-melanoma differentiation-associated gene 5 (MDA5) antibodies were detected using enzyme-linked immunosorbent assay (ELISA). Variables were compared between patients with and those without PNM. Multivariate analysis was performed using a multivariate logistic regression model. A total of 11 patients developed spontaneous PNM. During the follow-up period, 6 patients died of respiratory failure. No differences in sex, age at the onset of DM, serum ferritin levels, and C-reactive protein (CRP) levels were observed between DM patients with and without PNM. Compared with DM patients without PNM, those with PNM had significantly higher frequencies of rapidly progressive ILD (RP-ILD) (63.6 vs 24.4 %, P = 0.01), anti-MDA5 antibodies (90.9 vs 52.4 %, P = 0.02), CADM diagnoses (63.6 vs 22.0 %, P = 0.007) and cutaneous ulcers (36.4 vs 11 %, P = 0.04), but significantly lower creatine kinase (CK) levels (58.5 vs 284 U/l, P = 0.04). The multivariate analysis indicated that cutaneous ulcer was the only independent risk factor for the occurrence of PNM in DM (OR = 5.98, 95 % confidence interval [CI] 1.12-31.98, P = 0.037). PNM is a refractory complication and tends to occur in DM patients with RP-ILD, anti-MDA5 antibody, CADM diagnosis, and low CK level, and especially in patients with cutaneous ulcers.

Citing Articles

Antimelanoma differentiation-associated gene 5 (anti-MDA5) antibody-positive dermatomyositis: clinical features and outcomes in a racially diverse patient cohort.

Koyoda S, Ezzy F, Wahezi D, Kumthekar A, Xie X, Tagoe C BMC Rheumatol. 2025; 9(1):5.

PMID: 39789667 PMC: 11715331. DOI: 10.1186/s41927-025-00455-5.


Comparison of the use of venovenous extracorporeal membrane oxygenation in anti-melanoma differentiation-associated protein 5 positive dermatomyositis and other systemic rheumatic diseases associated with acute respiratory failure based on a....

Wang L, Wu X, He S, Wang X, Wang W, Chen Y J Thorac Dis. 2024; 16(10):6516-6524.

PMID: 39552869 PMC: 11565323. DOI: 10.21037/jtd-24-650.


Critical Crossroads: The Vital Role of Timely Diagnosis in Severe Amyopathic Dermatomyositis.

Monteiro A, Santana T, Tomas A, Negrao C, Matos C Cureus. 2024; 16(10):e70875.

PMID: 39497880 PMC: 11532934. DOI: 10.7759/cureus.70875.


Tension Pneumomediastinum in Anti-MDA5 Antibody-positive Dermatomyositis-associated Interstitial Lung Disease: A Case Report and Literature Review.

Okabayashi H, Nakashima S, Fujino K, Imai M, Hamada S, Masunaga A Intern Med. 2024; 63(23):3221-3226.

PMID: 38569903 PMC: 11671188. DOI: 10.2169/internalmedicine.3418-23.


Dermatomyositis: Practical Guidance and Unmet Needs.

Cassard L, Seraly N, Riegert M, Patel A, Fernandez A Immunotargets Ther. 2024; 13:151-172.

PMID: 38464459 PMC: 10924937. DOI: 10.2147/ITT.S381472.


References
1.
Sontheimer R . Clinically amyopathic dermatomyositis: what can we now tell our patients?. Arch Dermatol. 2010; 146(1):76-80. DOI: 10.1001/archdermatol.2009.323. View

2.
Kameda H, Nagasawa H, Ogawa H, Sekiguchi N, Takei H, Tokuhira M . Combination therapy with corticosteroids, cyclosporin A, and intravenous pulse cyclophosphamide for acute/subacute interstitial pneumonia in patients with dermatomyositis. J Rheumatol. 2005; 32(9):1719-26. View

3.
Zou J, Li T, Huang X, Chen S, Guo Q, Bao C . Basiliximab may improve the survival rate of rapidly progressive interstitial pneumonia in patients with clinically amyopathic dermatomyositis with anti-MDA5 antibody. Ann Rheum Dis. 2014; 73(8):1591-3. DOI: 10.1136/annrheumdis-2014-205278. View

4.
Ando M, Miyazaki E, Yamasue M, Sadamura Y, Ishii T, Takenaka R . Successful treatment with tacrolimus of progressive interstitial pneumonia associated with amyopathic dermatomyositis refractory to cyclosporine. Clin Rheumatol. 2010; 29(4):443-5. DOI: 10.1007/s10067-009-1358-x. View

5.
Gono T, Kawaguchi Y, Hara M, Masuda I, Katsumata Y, Shinozaki M . Increased ferritin predicts development and severity of acute interstitial lung disease as a complication of dermatomyositis. Rheumatology (Oxford). 2010; 49(7):1354-60. DOI: 10.1093/rheumatology/keq073. View